New hope for shock patients: valve repair may save lives
NCT ID NCT05298124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a minimally invasive procedure to repair a leaky heart valve in people with cardiogenic shock, a life-threatening condition where the heart can't pump enough blood. About 144 adults in intensive care will be randomly assigned to either standard medical therapy or the valve repair. The goal is to see if the repair reduces deaths, need for a heart transplant or a mechanical heart pump, or need for long-term heart-supporting medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 144 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants or substitute decision maker is able and willing to provide written informed consent 2. Age ≥ 18 years 3. SCAI stage C or D cardiogenic shock with persistent inotrope/vasopressor/non-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization 4. Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE) 5. In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve \<3+ MR Exclusion Criteria: 1. Unwilling or unable to obtain informed consent from the participant or substitute decision maker 2. Revascularization of coronary artery disease performed in the 48 hours prior to randomization 3. If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention 4. Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring) 5. Echocardiographic evidence of left sided intracardiac mass or thrombus 6. Diagnosis of active infective endocarditis 7. Transesophageal echocardiogram is contraindicated 8. Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team 9. Any aortic valve disease greater than moderate in severity 10. A known hypersensitivity or contraindication to procedure medications which cannot be adequately managed medically 11. Out of hospital cardiac arrest or in-hospital cardiac arrest without documented neurologic recovery 12. Plan for durable mechanical circulatory support implantation prior to TMVr 13. In the opinion of the treating team, there is a significant comorbidity that would limit life expectancy in hospital 14. Pregnant or planning to become pregnant in the next 6 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
St. Michael's Hospital
NOT_YET_RECRUITINGToronto, Ontario, M5B 1T8, Canada
-
Sunnybrook Hospital
NOT_YET_RECRUITINGToronto, Ontario, M4N 3M5, Canada
-
University of Ottawa Heart Institute
RECRUITINGOttawa, Ontario, K1Y4W7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stick-On patch aims to catch dangerous heart decline sooner
- Earlier blood thinner may cut clot risk in heart procedures
- Heart pump timing put to the test in deadly heart attack shock
- A second chance for the heart: can rehab rewrite the story after shock?
- A simple pressure reading may expose hidden mitral valve leakage after keyhole repair
- Blood filter may calm the deadly inflammation of cardiogenic shock